Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 0.71 |
| ▸ | ACE | P12821 | 4/20 | 0.71 |
| ▸ | MMEL1 | Q495T6 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908574 | 0.91 | MME (0.59) | MMEACEMMEL1 | |
| SCHEMBL7436015 | 0.89 | MME (0.76) | MMEACEMMEL1 | |
| SCHEMBL28456484 | 0.89 | MME (0.76) | MMEACEMMEL1 | |
| SCHEMBL22585406 | 0.88 | MME (0.74) | MMEACEMMEL1 | |
| SCHEMBL22556619 | 0.87 | MME (0.80) | MMEACEMMEL1 | |
| SCHEMBL22556618 | 0.87 | MME (0.80) | MMEACEMMEL1 | |
| SCHEMBL28450664 | 0.85 | MME (0.77) | MMEACEMMEL1 | |
| SCHEMBL28450662 | 0.85 | MME (0.77) | MMEACEMMEL1 | |
| SCHEMBL17169811 | 0.84 | MME (0.76) | MMEACEMMEL1 | |
| SCHEMBL17169875 | 0.84 | MME (0.69) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121578-B1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8716495-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| EP-2121578-A2 | NEW PROCESS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.